
Alexion has received marketing authorisation from the European Commission for its long-acting C5 complement inhibitor Ultomiris (ravulizumab) in the treatment …

Alexion has lifted the curtain on new data for its C5 complement inhibitor ALXN1210, demonstrating its non-inferiority to another of …

